RNS60 has undergone rigorous testing both in cell-based in vitro assays and in vivo disease models. RNS60 acts in a broad-based manner to change the responsiveness of epithelial cells, smooth muscle cells, and immune cells to inflammatory stimuli that can trigger an asthma attack. We have shown that RNS60 alters whole cell conductance through effects on voltage-gated ion channels and potentially other voltage-sensing proteins. RNS60 modulates expression of G protein-coupled receptors and secretion of cytokines, chemokines and adhesion molecules.
We tested RNS60 alone or in combination with budesonide, an FDA-approved inhalant steroid for the prevention of asthma attacks, in the ovalbumin challenge model in rats, a widely accepted rodent model of human allergic asthma. Animals treated with RNS60 showed an immediate threefold improvement in tidal volume. In addition, RNS60 achieved the significant downregulation of inflammatory cytokines and chemokines in the blood and in bronchoalveolar lavage fluid 24 hours after the asthma challenge.
PRE-CLINICAL TOXICITY STUDIES
In preparation for the IND filing for RNS60, comprehensive toxicity studies were conducted. RNS60 did not display any toxic properties in these tests.
Revalesio is optimistic that the development plan for RNS60 will lead to a novel treatment for asthma, and potentially for COPD, cystic fibrosis and allergic rhinitis. Revalesio is seeking partners for development and commercialization of RNS60.